亚虹医药(688176.SH):APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)完成II期临床首例受试者入组

智通财经
Dec 12, 2022

智通财经APP讯,亚虹医药(688176.SH)公告,公司开展的APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)临床试验,于近日完成II期临床试验首例受试者入组。

据悉,APL-1202(商品名唯施可®)是一款口服的可逆性MetAP2抑制剂,具有抗血管生成、抗肿瘤活性及调节肿瘤免疫微环境的作用。临床前研究显示,APL1202与PD-1单抗联合用药在膀胱癌药效学模型上显示出协同作用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10